| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| tPA/HisproUK (Thrombolytic Science) | TS-01 | Phase 2 Clinical | Thrombolytic Science | Ischemic Stroke | Details |
| Upamostat Hydrogen Sulphate | WX-671; LH-011; RHB-107 | Phase 2 Clinical | Wilex AG | Coronavirus Disease 2019 (COVID-19); Metastatic breast cancer; Pancreatic Neoplasms | Details |
| Microlyse | TGD-001 | Phase 2 Clinical | University Medical Centre Utrecht, Netherlands | Ischemic Stroke; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies | Details |
| Recombinant annexin A5 (Annexin Pharmaceuticals) | ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5) | Phase 2 Clinical | Annexin Pharmaceuticals AB | Anemia, Sickle Cell; Cardiovascular Diseases; Diabetic Retinopathy; Neoplasms; Retinal Vein Occlusion | Details |
| MSB-03 | MSB-03 | Phase 1 Clinical | MatriSys Bioscience Inc | Rosacea | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Urokinase biosimilar (Sedico) | Approved | Sedico | Angikinase | Egypt | Thromboembolism; Myocardial Infarction; Pulmonary Embolism | Sedico | 2014-01-01 | Myocardial Infarction; Pulmonary Embolism; Thromboembolism | Details | |
| Tisokinase | AK-124 | Approved | Asahi Kasei Corp, Kowa Dental Health Co Ltd | Plasvata, Hapase | Japan | Myocardial Infarction; Thrombosis | null | 1991-01-01 | Myocardial Infarction; Thrombosis | Details |
| Urokinase biosimilar (Bharat Serums & Vaccines) | U-FRAG | Approved | Bharat Serums And Vaccines Ltd | Pulmonary Embolism | Details | |||||
| Nasaruplase | GE-0943 | Approved | Mitsubishi Pharma Corp | Tomieze, Thrombolyse | Japan | Myocardial Infarction; Venous Thrombosis | Mitsubishi Pharma Corp | 1992-01-01 | Myocardial Infarction; Venous Thrombosis | Details |